دورية أكاديمية

Nanomedicine as a multimodal therapeutic paradigm against cancer: on the way forward in advancing precision therapy.

التفاصيل البيبلوغرافية
العنوان: Nanomedicine as a multimodal therapeutic paradigm against cancer: on the way forward in advancing precision therapy.
المؤلفون: Sandbhor P; Institute for NanoBioTechnology, Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD, 21218, USA. p00jasandbhor@gmail.com., Palkar P; Radiobiology, Department of Radiation Oncology & Homi Bhabha National Institute, Mumbai, 400012, India., Bhat S; Radiobiology, Department of Radiation Oncology & Homi Bhabha National Institute, Mumbai, 400012, India., John G; Radiobiology, Department of Radiation Oncology & Homi Bhabha National Institute, Mumbai, 400012, India., Goda JS; Radiobiology, Department of Radiation Oncology & Homi Bhabha National Institute, Mumbai, 400012, India.
المصدر: Nanoscale [Nanoscale] 2024 Mar 28; Vol. 16 (13), pp. 6330-6364. Date of Electronic Publication: 2024 Mar 28.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: RSC Pub Country of Publication: England NLM ID: 101525249 Publication Model: Electronic Cited Medium: Internet ISSN: 2040-3372 (Electronic) Linking ISSN: 20403364 NLM ISO Abbreviation: Nanoscale Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Cambridge, UK : RSC Pub.
مواضيع طبية MeSH: Neoplasms*/drug therapy , Nanoparticles*/therapeutic use, Humans ; Nanomedicine ; Nanotechnology ; Drug Delivery Systems ; Theranostic Nanomedicine ; Tumor Microenvironment
مستخلص: Recent years have witnessed dramatic improvements in nanotechnology-based cancer therapeutics, and it continues to evolve from the use of conventional therapies (chemotherapy, surgery, and radiotherapy) to increasingly multi-complex approaches incorporating thermal energy-based tumor ablation ( e.g. magnetic hyperthermia and photothermal therapy), dynamic therapy ( e.g. photodynamic therapy), gene therapy, sonodynamic therapy ( e.g. ultrasound), immunotherapy, and more recently real-time treatment efficacy monitoring ( e.g. theranostic MRI-sensitive nanoparticles). Unlike monotherapy, these multimodal therapies (bimodal, i.e. , a combination of two therapies, and trimodal, i.e. , a combination of more than two therapies) incorporating nanoplatforms have tremendous potential to improve the tumor tissue penetration and retention of therapeutic agents through selective active/passive targeting effects. These combinatorial therapies can correspondingly alleviate drug response against hypoxic/acidic and immunosuppressive tumor microenvironments and promote/induce tumor cell death through various multi-mechanisms such as apoptosis, autophagy, and reactive oxygen-based cytotoxicity, e.g. , ferroptosis, etc. These multi-faced approaches such as targeting the tumor vasculature, neoangiogenic vessels, drug-resistant cancer stem cells (CSCs), preventing intra/extravasation to reduce metastatic growth, and modulation of antitumor immune responses work complementary to each other, enhancing treatment efficacy. In this review, we discuss recent advances in different nanotechnology-mediated synergistic/additive combination therapies, emphasizing their underlying mechanisms for improving cancer prognosis and survival outcomes. Additionally, significant challenges such as CSCs, hypoxia, immunosuppression, and distant/local metastasis associated with therapy resistance and tumor recurrences are reviewed. Furthermore, to improve the clinical precision of these multimodal nanoplatforms in cancer treatment, their successful bench-to-clinic translation with controlled and localized drug-release kinetics, maximizing the therapeutic window while addressing safety and regulatory concerns are discussed. As we advance further, exploiting these strategies in clinically more relevant models such as patient-derived xenografts and 3D organoids will pave the way for the application of precision therapy.
تواريخ الأحداث: Date Created: 20240312 Date Completed: 20240329 Latest Revision: 20240329
رمز التحديث: 20240329
DOI: 10.1039/d3nr06131k
PMID: 38470224
قاعدة البيانات: MEDLINE
الوصف
تدمد:2040-3372
DOI:10.1039/d3nr06131k